Presentation (CTI)

OBJECTIVES: If the conclusion is knowable before the assessment begins, what is the assessment measuring? This analysis used the first orphan oncology JCA, tovorafenib for paediatric low-grade glioma, supported by a single-arm trial, to test whether single-arm-supported products can be meaningfully assessed under the current framework.
METHODS: A case analysis examined how the published JCA report handled single-arm pivotal evidence and the unanchored indirect comparison built upon it, assessed against HTACG methodological guidance and the comparative-effectiveness paradigm the framework embeds.
RESULTS: The framework's comparative-effectiveness logic presumes a controlled comparison the evidence could not supply. With a single-arm pivotal study and no common comparator, the assessment defaulted toward findings dominated by uncertainty rather than demonstrated relative effect, an outcome largely foreseeable from the design before the process began. When the result is effectively predetermined by trial architecture, the exercise reproduces its own assumptions rather than measuring the product, consuming substantial assessor and developer effort for limited informational return. This does not endorse single-arm designs; it questions the fit between such evidence and a comparative audit. The pattern is likely to recur across rare-disease and advanced-therapy products that rely on single-arm evidence already accepted for regulatory authorisation.
CONCLUSIONS: A process whose outcome is fixed in advance is not an assessment. Either single-arm-supported products warrant a distinct, fit-for-purpose pathway, or the framework should articulate transparently how such evidence can yield a usable comparative conclusion.